Specifically, future studies should clarify the relationship between serum galectin-3 and cardiovascular mortality and evaluate additional endpoints, such as the incidence of heart failure, atrial fibrillation and sudden cardiac death. Here, LGALS3 is linked to atrial fibrillation.